Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial

CHARISMA Investigators, Peter B Berger, Deepak L Bhatt, Valentin Fuster, P Gabriel Steg, Keith A A Fox, Mingyuan Shao, Danielle M Brennan, Werner Hacke, Gilles Montalescot, Steven R Steinhubl, Eric J Topol

Research output: Contribution to journalArticlepeer-review

Abstract

Uncertainty exists about the frequency, correlates, and clinical significance of bleeding with dual antiplatelet therapy (DAPT), particularly over an extended period in a stable population. We sought to determine the frequency and time course of bleeding with DAPT in patients with established vascular disease or risk factors only; identify correlates of bleeding; and determine whether bleeding is associated with mortality.
Original languageEnglish
Pages (from-to)2575-83
Number of pages9
JournalCirculation
Volume121
Issue number23
DOIs
Publication statusPublished - 2010

Fingerprint

Dive into the research topics of 'Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial'. Together they form a unique fingerprint.

Cite this